This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chung, M. K. Articles by Tchou, P. J. Search for Related Content PubMed PubMed Citation Articles by Chung, M. K. Articles by Tchou, P. J.

CLINICAL STUDIES

Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?

yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications

^a Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^* Ischemia Research and Education Foundation, San Francisco, California, USA

Manuscript received December 16, 1997; revised manuscript received March 2, 1998, accepted March 16, 1998.

Address for correspondence: Dr. Mina K. Chung, Department of Cardiology, Section of Electrophysiology and Pacing, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F-15, Cleveland, Ohio 44195
chungm{at}cesmtp.ccf.org

Objectives. We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation.

Background. The need for hospital admission during initiation of antiarrhythmic therapy has been questioned, particularly for sotalol, with which proarrhythmia may be dose related.

Methods. The records of 120 patients admitted to the hospital for initiation of sotalol therapy were retrospectively reviewed to determine the incidence of significant arrhythmia complications, defined as new or increased ventricular arrhythmias, significant bradycardia or excessive corrected QT (QTc) interval prolongation.

Results. Twenty-five patients (20.8%) experienced 35 complications, triggering therapy changes during the hospital period in 21 (17.5%). New or increased ventricular arrhythmias developed in 7 patients (5.8%) (torsade de pointes in 2), significant bradycardia in 20 (16.7%) (rate <40 beats/min in 13, pause >3.0 s in 4, third-degree atrioventricular block in 1, permanent pacemaker implantation in 3) and excessively prolonged QTc intervals in 8 (6.7%) (dosage reduced or discontinued in 6). Time to the earliest detection of complications was 2.1 ± 2.5 (mean ± SD) days after initiation of sotalol, with 22 of 25 patients meeting criteria for complications within 3 days of monitoring. Baseline electrocardiographic intervals or absence of heart disease failed to distinguish a low risk group. Multivariate analysis identified absence of a pacemaker as the only significant predictor of arrhythmia complications (p = 0.022).

Conclusions. Because clinically significant complications can be detected with in-hospital monitoring in one of five patients starting sotalol therapy, hospital admission is warranted for initiation of sotalol. Patients without pacemakers are at higher risk for these complications.

Abbreviations and Acronyms   ECG = electrocardiogram, electrocardiographic   ICD = implantable cardioverter-defibrillator

This article has been cited by other articles:

				S. M. Al-Khatib, N. M. A. LaPointe, J. M. Kramer, and R. M. Califf What Clinicians Should Know About the QT Interval JAMA, April 23, 2003; 289(16): 2120 - 2127. [Abstract] [Full Text] [PDF]

				V. Essebag, T. Hadjis, R. W. Platt, and L. Pilote Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction J. Am. Coll. Cardiol., January 15, 2003; 41(2): 249 - 254. [Abstract] [Full Text] [PDF]

				B. Darpo Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80. [Abstract] [PDF]

				A Plewan, G Lehmann, G Ndrepepa, J Schreieck, E.U Alt, A Schomig, and C Schmitt Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs bisoprolol Eur. Heart J., August 2, 2001; 22(16): 1504 - 1510. [Abstract] [PDF]

				Sotalol Causes Significant Arrhythmias Journal Watch Emergency Medicine, October 1, 1998; 1998(1001): 10 - 10. [Full Text]